LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept - Coskun, Tamer; Sloop, Kyle W.; Loghin, Corina; Alsina-Fernandez, Jorge; Urva, Shweta; Bokvist, Krister B.; Cui, Xuewei; Briere, Daniel A.; Cabrera, Over; Roell, William C.; Kuchibhotla, Uma; Moyers, Julie S.; et al. (Molecular metabolism (Germany), 2018)
Keywords: Adult; Animals; Appetite - drug effects; Blood Glucose - metabolism; Body Weight; Diabetes Mellitus, Type 2 - drug therapy; Diarrhea - etiology; Female; Gastric Inhibitory Polypeptide - adverse effects; Gastric Inhibitory Polypeptide - pharmacology; Gastric Inhibitory Polypeptide - therapeutic use; Glucagon-like peptide-1; Glucagon-Like Peptide-1 Receptor - agonists; Glucose-dependent insulinotropic polypeptide; Humans; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - pharmacology; Hypoglycemic Agents - therapeutic use; Incretins - adverse effects; Incretins - pharmacology; Incretins - therapeutic use; LY3298176; Male; Mice; Mice, Inbred C57BL; Middle Aged; Obesity; Original; Receptors, Gastrointestinal Hormone - agonists; Type 2 diabetes mellitus; Vomiting - etiology; T2DM; CNS; Type 2 diabetes mellitus; HS; LY; DU; Obesity; GLP-1 RA; LY3298176; Glucose-dependent insulinotropic polypeptide; POC; CI; LSM; ECG; DIO; GIP; MAD; Glucagon-like peptide-1; SAD; SMBG; ipGTT; PL; OGTT; ADA; MMRM